Across TCGA pan-cancer cohorts, LIN9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LIN9 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher LIN9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LIN9 expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

GBM, LUAD, and LSCC are the cancer types where LIN9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.439	0.259	.019	11	view →
LUAD	DFS	Median	II,III,IV	0.215	0.790	.004	10	view →
LSCC	DFS	Median	All	0.464	0.907	.009	6	view →
PDAC	DFS	Tertile	All	0.379	0.747	.022	4	view →
CCRCC	OS	Tertile	All	1.000	0.857	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: LIN9 tumor-vs-normal RNA expression · all LIN9 data types